Aegerion Pharmaceuticals and QLT Inc. have entered a merger agreement under which Aegerion will be merged with a wholly owned indirect subsidiary of QLT. When the transaction is completed, QLT will change the combined company’s name to Novelion Therapeutics. The deal is expected to close late in the third quarter or during the fourth quarter of 2016. The merger is expected to create a strong, rare disease-focused global biopharmaceutical company with a diversified portfolio consisting of Aege...